Catastrophic failures of freezing bags for cellular therapy products

Description, cause, and consequences

H. M. Khuu, H. Cowley, V. David-Ocampo, C. S. Carter, Claude Sportes, A. S. Wayne, S. R. Solomon, M. R. Bishop, R. M. Childs, E. J. Read

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: Container integrity is critical for maintaining sterility of cryopreserved cellular therapy products. We investigated a series of catastrophic bag failures, first noticed in early 2001. Methods: Process records were reviewed for all PBPC and lymphocyte products cryopreserved in bags from January 2000 through April 2002. Patient charts were also reviewed. Results: One thousand two hundred and four bags were removed from storage for infusion to 261 patients. All products had been cryopreserved in Cryocyte poly(ethylene co-vinyl acetate) (EVA) bags in either 10% DMSO or 5% DMSO and 6% pentastarch. Product volumes were 25-75 mL, and bags were stored with overwrap bags in a liquid nitrogen tank. From January 2000 to April 2001, failure occurred in 10 of 599 (1.7%) bags. From May 2001 to April 2002, 58 of 605 (9.6%) bags failed, typically with extensive fractures that were visible before thaw. Of the 58 that failed, 24 were salvaged by aseptic methods and infused to patients under antibiotic coverage; 10 of those 24 (42%) had positive bacterial cultures. Bag failures were not related to product type, cryoprotectant solution, liquid versus vapor storage, or freezer location. Failures were linked to use of four Cryocyte bag lots manufactured in 2000 and 2001. After replacing these lots with a 1999 Cryocyte lot and with KryoSafe polyfluoroethylene polyfluoropropylene (FEP) bags, no more failures occurred in 75 and 102 bags, respectively, thawed through April 2002. Discussion: High rates of bag failure were associated with four Cryocyte bag lots. No serious adverse patient effects occurred, but bag failures led to microbial contamination, increased product preparation time, increased antibiotic use, and increased resource expenditure to replace products.

Original languageEnglish (US)
Pages (from-to)539-549
Number of pages11
JournalCytotherapy
Volume4
Issue number6
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

Freezing
Dimethyl Sulfoxide
Hydroxyethyl Starch Derivatives
Anti-Bacterial Agents
Polytetrafluoroethylene
Therapeutics
Health Expenditures
Infertility
Nitrogen
Lymphocytes

Keywords

  • Aseptic methods
  • Bacterial contamination
  • Cellular therapy product
  • Cryopreservation
  • Plastic bags

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Genetics(clinical)
  • Cell Biology
  • Transplantation
  • Cancer Research

Cite this

Khuu, H. M., Cowley, H., David-Ocampo, V., Carter, C. S., Sportes, C., Wayne, A. S., ... Read, E. J. (2002). Catastrophic failures of freezing bags for cellular therapy products: Description, cause, and consequences. Cytotherapy, 4(6), 539-549. https://doi.org/10.1080/146532402761624700

Catastrophic failures of freezing bags for cellular therapy products : Description, cause, and consequences. / Khuu, H. M.; Cowley, H.; David-Ocampo, V.; Carter, C. S.; Sportes, Claude; Wayne, A. S.; Solomon, S. R.; Bishop, M. R.; Childs, R. M.; Read, E. J.

In: Cytotherapy, Vol. 4, No. 6, 01.01.2002, p. 539-549.

Research output: Contribution to journalArticle

Khuu, HM, Cowley, H, David-Ocampo, V, Carter, CS, Sportes, C, Wayne, AS, Solomon, SR, Bishop, MR, Childs, RM & Read, EJ 2002, 'Catastrophic failures of freezing bags for cellular therapy products: Description, cause, and consequences', Cytotherapy, vol. 4, no. 6, pp. 539-549. https://doi.org/10.1080/146532402761624700
Khuu, H. M. ; Cowley, H. ; David-Ocampo, V. ; Carter, C. S. ; Sportes, Claude ; Wayne, A. S. ; Solomon, S. R. ; Bishop, M. R. ; Childs, R. M. ; Read, E. J. / Catastrophic failures of freezing bags for cellular therapy products : Description, cause, and consequences. In: Cytotherapy. 2002 ; Vol. 4, No. 6. pp. 539-549.
@article{e2e753436737402ebda0c94a21cd08c0,
title = "Catastrophic failures of freezing bags for cellular therapy products: Description, cause, and consequences",
abstract = "Background: Container integrity is critical for maintaining sterility of cryopreserved cellular therapy products. We investigated a series of catastrophic bag failures, first noticed in early 2001. Methods: Process records were reviewed for all PBPC and lymphocyte products cryopreserved in bags from January 2000 through April 2002. Patient charts were also reviewed. Results: One thousand two hundred and four bags were removed from storage for infusion to 261 patients. All products had been cryopreserved in Cryocyte poly(ethylene co-vinyl acetate) (EVA) bags in either 10{\%} DMSO or 5{\%} DMSO and 6{\%} pentastarch. Product volumes were 25-75 mL, and bags were stored with overwrap bags in a liquid nitrogen tank. From January 2000 to April 2001, failure occurred in 10 of 599 (1.7{\%}) bags. From May 2001 to April 2002, 58 of 605 (9.6{\%}) bags failed, typically with extensive fractures that were visible before thaw. Of the 58 that failed, 24 were salvaged by aseptic methods and infused to patients under antibiotic coverage; 10 of those 24 (42{\%}) had positive bacterial cultures. Bag failures were not related to product type, cryoprotectant solution, liquid versus vapor storage, or freezer location. Failures were linked to use of four Cryocyte bag lots manufactured in 2000 and 2001. After replacing these lots with a 1999 Cryocyte lot and with KryoSafe polyfluoroethylene polyfluoropropylene (FEP) bags, no more failures occurred in 75 and 102 bags, respectively, thawed through April 2002. Discussion: High rates of bag failure were associated with four Cryocyte bag lots. No serious adverse patient effects occurred, but bag failures led to microbial contamination, increased product preparation time, increased antibiotic use, and increased resource expenditure to replace products.",
keywords = "Aseptic methods, Bacterial contamination, Cellular therapy product, Cryopreservation, Plastic bags",
author = "Khuu, {H. M.} and H. Cowley and V. David-Ocampo and Carter, {C. S.} and Claude Sportes and Wayne, {A. S.} and Solomon, {S. R.} and Bishop, {M. R.} and Childs, {R. M.} and Read, {E. J.}",
year = "2002",
month = "1",
day = "1",
doi = "10.1080/146532402761624700",
language = "English (US)",
volume = "4",
pages = "539--549",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Catastrophic failures of freezing bags for cellular therapy products

T2 - Description, cause, and consequences

AU - Khuu, H. M.

AU - Cowley, H.

AU - David-Ocampo, V.

AU - Carter, C. S.

AU - Sportes, Claude

AU - Wayne, A. S.

AU - Solomon, S. R.

AU - Bishop, M. R.

AU - Childs, R. M.

AU - Read, E. J.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Background: Container integrity is critical for maintaining sterility of cryopreserved cellular therapy products. We investigated a series of catastrophic bag failures, first noticed in early 2001. Methods: Process records were reviewed for all PBPC and lymphocyte products cryopreserved in bags from January 2000 through April 2002. Patient charts were also reviewed. Results: One thousand two hundred and four bags were removed from storage for infusion to 261 patients. All products had been cryopreserved in Cryocyte poly(ethylene co-vinyl acetate) (EVA) bags in either 10% DMSO or 5% DMSO and 6% pentastarch. Product volumes were 25-75 mL, and bags were stored with overwrap bags in a liquid nitrogen tank. From January 2000 to April 2001, failure occurred in 10 of 599 (1.7%) bags. From May 2001 to April 2002, 58 of 605 (9.6%) bags failed, typically with extensive fractures that were visible before thaw. Of the 58 that failed, 24 were salvaged by aseptic methods and infused to patients under antibiotic coverage; 10 of those 24 (42%) had positive bacterial cultures. Bag failures were not related to product type, cryoprotectant solution, liquid versus vapor storage, or freezer location. Failures were linked to use of four Cryocyte bag lots manufactured in 2000 and 2001. After replacing these lots with a 1999 Cryocyte lot and with KryoSafe polyfluoroethylene polyfluoropropylene (FEP) bags, no more failures occurred in 75 and 102 bags, respectively, thawed through April 2002. Discussion: High rates of bag failure were associated with four Cryocyte bag lots. No serious adverse patient effects occurred, but bag failures led to microbial contamination, increased product preparation time, increased antibiotic use, and increased resource expenditure to replace products.

AB - Background: Container integrity is critical for maintaining sterility of cryopreserved cellular therapy products. We investigated a series of catastrophic bag failures, first noticed in early 2001. Methods: Process records were reviewed for all PBPC and lymphocyte products cryopreserved in bags from January 2000 through April 2002. Patient charts were also reviewed. Results: One thousand two hundred and four bags were removed from storage for infusion to 261 patients. All products had been cryopreserved in Cryocyte poly(ethylene co-vinyl acetate) (EVA) bags in either 10% DMSO or 5% DMSO and 6% pentastarch. Product volumes were 25-75 mL, and bags were stored with overwrap bags in a liquid nitrogen tank. From January 2000 to April 2001, failure occurred in 10 of 599 (1.7%) bags. From May 2001 to April 2002, 58 of 605 (9.6%) bags failed, typically with extensive fractures that were visible before thaw. Of the 58 that failed, 24 were salvaged by aseptic methods and infused to patients under antibiotic coverage; 10 of those 24 (42%) had positive bacterial cultures. Bag failures were not related to product type, cryoprotectant solution, liquid versus vapor storage, or freezer location. Failures were linked to use of four Cryocyte bag lots manufactured in 2000 and 2001. After replacing these lots with a 1999 Cryocyte lot and with KryoSafe polyfluoroethylene polyfluoropropylene (FEP) bags, no more failures occurred in 75 and 102 bags, respectively, thawed through April 2002. Discussion: High rates of bag failure were associated with four Cryocyte bag lots. No serious adverse patient effects occurred, but bag failures led to microbial contamination, increased product preparation time, increased antibiotic use, and increased resource expenditure to replace products.

KW - Aseptic methods

KW - Bacterial contamination

KW - Cellular therapy product

KW - Cryopreservation

KW - Plastic bags

UR - http://www.scopus.com/inward/record.url?scp=0036926816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036926816&partnerID=8YFLogxK

U2 - 10.1080/146532402761624700

DO - 10.1080/146532402761624700

M3 - Article

VL - 4

SP - 539

EP - 549

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 6

ER -